<?xml version="1.0" encoding="UTF-8"?>
<p id="par0105">a.] To follow standard procedures and recommendations for thawing and transfusion of plasma; b.] It is crucial to ensure ABO compatibility between the donor and the recipient; c.] Transfusion of plasma from at least two donors may be therapeutically beneficial to achieve a more effective immune protection from delivery of diverse antibodies; d.] In the absence of published peer-reviewed reports of transfusion of convalescent COVID-19 plasma, patients could receive an initial dose of 200 mL, followed by one or two additional doses of 200 mL according to disease severity and tolerance of the infusions: e.] Further information on blood/serum/plasma samples of the recipient prior to and after transfusion should be taken for future potential scientific investigations. Details can be found in the following WHO document*at 
 <ext-link ext-link-type="uri" xlink:href="http://www.who.int/bloodproducts/brn" id="intr0005" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.who.int/bloodproducts/brn</ext-link>).
</p>
